Clinical trials located in

Bratislava

Bratislava city is located in Slovakia. Currently, 20 clinical trials are being conducted in this city.

Bratislava, the capital of Slovakia, nestles along the Danube River, bordering Austria and Hungary. It’s known for its medieval Old Town and the imposing Bratislava Castle, which stands on a plateau offering expansive views. The city uniquely blends various architectural styles, from Gothic to Baroque and modern. It was once part of the Kingdom of Hungary and has a rich history, including being the coronation site for Hungarian kings. The UFO Bridge, another highlight, showcases the city’s contemporary side.

  • CT-EU-00117573

    To evaluate a combination of 3 different drugs versus 2 other drugs in the treatment of patients with melanoma

    This study compares two different approaches to treating advanced melanoma, a type of skin cancer that has spread to other parts of the body. This study is specifically aimed at patients with a gene mutation called BRAF who have previously received treatment with drugs such as nivolumab or pembrolizumab.

    One therapeutic approach involves taking three study drugs: pembrolizumab administered intravenously every 3 weeks, along with encorafenib and binimetinib taken orally daily at home. The second approach involves taking two study drugs: ipilimumab and nivolumab administered intravenously every 3 weeks for the first 4 doses, followed by nivolumab alone every 4 weeks. Both treatments will last for approximately 2 years, but there is no time limit for treatment with encorafenib and binimetinib.

    The research team will closely monitor the patients’ health during regular clinic visits to see how they are responding to treatment. The main goal is to determine which treatment method is more effective in shrinking or eliminating melanoma tumors.

    • Nivolumab
    • Ipilimumab
    • Binimetinib
    • Encorafenib
    • Pembrolizumab
  • Study of a new drug for moderate to severe Rotator Cuff Tendinopathy

    The clinical trial examines the use of secukinumab, a drug, for treating moderate to severe rotator cuff tendinopathy—a shoulder condition characterized by pain and limited movement. The study explores whether secukinumab can improve symptoms and physical function compared to a placebo. Participants will receive either the drug or placebo in addition to standard care, under a randomized, double-blind, and placebo-controlled setup, to ensure the results are unbiased.

    • placebo
    • Secukinumab
  • Study Comparing Asciminib and Nilotinib for Newly Diagnosed Chronic Myeloid Leukemia

    This study examines the effects and tolerance of two drugs, asciminib and nilotinib, for treating a specific type of leukemia called Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in its chronic phase. The participants are adults who have been newly diagnosed and have not received previous treatment for this condition. They will be randomly assigned to receive either asciminib or nilotinib. The study aims to see which drug is better tolerated and how effective they are. Throughout the study, participants will be monitored for any side effects and the progress of their treatment until they either experience significant side effects, the disease progresses, or they decide to stop the treatment. Follow-up checks will also be conducted after the treatment ends.

    • Asciminib
    • Nilotinib
  • Study of the new oral drug LY3871801 for rheumatoid arthritis

    The aim of this study is to test a new drug called LY3871801 for people suffering from moderate to severe rheumatoid arthritis. The main goal is to see if this new drug can help reduce disease activity and improve symptoms better than a placebo. In the first part of the study, doctors will check how much the Disease Activity Score changes after 12 weeks of taking LY3871801 or a placebo. Then, in the second part, they will look at what percentage of patients experience significant improvement, defined as achieving an ACR50 response, which means reducing symptoms of rheumatoid arthritis by 50% or more. Both the real drug and the placebo will be taken by mouth.

    • placebo
    • LY3871801
  • Testing the effectiveness of new drugs in the treatment of age-related macular degeneration

    The study is investigating a potential breakthrough in treating age-related vision loss, specifically neovascular age-related macular degeneration (nAMD). It introduces a novel therapy, OPT-302, and pairs it with Aflibercept, comparing this combination’s effectiveness against the standard treatment. Participants undergo a series of thorough eye examinations and treatments to monitor the progression of their vision health. The research aims to offer a clearer understanding of how these treatments can better manage and possibly improve vision for individuals dealing with nAMD, contributing valuable knowledge to the field of eye health care.

    • aflibercept
    • OPT-302
  • Studying efficacy of volrustomig for metastatic lung cancer

    The study compared two treatments for metastatic non-small cell lung cancer: volrustomig with chemotherapy and pembrolizumab with chemotherapy. Its purpose is to determine which combination is more effective and safer. Patients will be divided into two groups. One group will receive volrustomig and chemotherapy, and the other group will receive pembrolizumab and chemotherapy. The effectiveness of treatment in each group will then be tracked using imaging tests. In addition, a group of researchers will follow each participant until the end of the study to make sure the treatment is safe and tolerable.

    • Volrustomig
    • Pemetrexed
    • Carboplatin
    • Pembrolizumab
    • Paclitaxel
  • Comparing a new treatment with standard care for advanced colorectal cancer

    This research study is for people suffering from a type of bowel cancer that has spread to other parts of the body, known as ‘metastatic colorectal cancer’. The purpose of the study is to compare a new combination of medications against the regular treatments that are already in use. Patients participating in the study will be placed into two groups: one group will receive the standard treatment, and the other group will try a new combination of drugs (tucatinib, trastuzumab, and 5-Fluorouracil, leucovorin,,oxaliplatin). This study will also help to understand the side effects, which are any unexpected symptoms or changes that can occur when taking these medications. Ultimately, the goal of this study is to help learn more about which treatment is more effective in delaying the progression of the disease and improving the patients’ quality of life.

    • levoleucovorin
    • leucovorin
    • Fluorouracil
    • Bevacizumab
    • Cetuximab
    • Tucatinib
    • Oxaliplatin
    • Trastuzumab
  • Iptacopan’s effect on adult patients with atypical hemolytic uremic syndrome

    This study is conducted to understand if a medicine called iptacopan (also known as LNP023) is safe and effective in treating a disease called Atypical Hemolytic Uremic Syndrome (aHUS) in adults who have never received a type of medication known as a complement inhibitor. Around 50 adults will be given 200 mg of this iptacopan pill twice a day. The doctors will measure how their illness responds by looking at blood tests, kidney health, how often they need to have their blood cleansed by a machine (dialysis), the progression of their kidney illness, and how they feel energetically and about their quality of life. Side effects of taking iptacopan will be recorded for a year.

    • Iptacopan
  • Study investigating new medicine for advanced metastatic breast cancer

    A clinical study is investigating the impact and safety of a new medicine named ARV-471 (Vepdegrestrant), contrasting its effects with an already-used drug called fulvestrant (FUL). This research targets individuals suffering from advanced metastatic breast cancer, a disease that often spreads to various parts of the body and is challenging to control. ARV-471 will be given to half of the participants, with the other half receiving fulvestrant. The effects of both will be monitored over time. ARV-471 is consumed by mouth, while FUL is administered through injections.

    • Vepdegrestrant/ARV-471
    • Fulvestrant
  • Evaluating the efficacy of macitentan in the treatment of high pulmonary artery blood pressure

    This study is checking if a 75 mg dose of a medicine called Macitentan can do a better job for patients with a lung condition called Pulmonary Arterial Hypertension (PAH) compared to a 10 mg dose. The main goal is to see if the 75 mg dose can better delay the patient’s first major health event related to PAH. Major events include things like unplanned hospital stays related to PAH, or their PAH getting worse. The researchers will check if patients’ PAH gets worse by looking at things like their physical exercise ability and signs of heart failure. The study also looks at how patients’ symptoms change from day to day.

    • macitentan
  • Study of alpelisib and fulvestrant for advanced breast cancer treatment

    This trial is looking at the effects of the combined use of two drugs, alpelisib and fulvestrant, in treating patients who have advanced breast cancer. The cancer should be HR-positive and HER2-negative, and have a specific mutation (PIK3CA). If the patients already underwent certain other treatments like CDK4/6 Inhibitors and aromatase Inhibitors, but the cancer has progressed, they could join this trial. Doctors will be able to compare the results of patients taking alpelisib and fulvestrant together, with those taking fulvestrant with a placebo, They aim to check which combination works better in delaying the advance of cancer or in improving a patient’s life duration.

    • Alpelisib
    • Fulvestrant
  • Comparing remibrutinib and teriflunomide for Multiple Sclerosis

    This study is all about comparing two treatments for relapsing multiple sclerosis (RMS)—a medicine called remibrutinib and another one called teriflunomide. Initially, researchers will do what’s known as a ‘double-blind, which means neither the participants nor the researchers know which treatment the participant takes. This part of the study will involve about 800 people and will go for up to 30 months. After this, the participants can continue the study openly taking remibrutinib for up to 5 years. The study will measure things like how often the MS relapses, changes in disability scale, amount of new lesions, changes in blood markers, walking and arm function, mood, pain, and deviations in various health parameters. There will be a lesser version trial simultaneously, with results from both pooled for analysis.

    • Teriflunomide
    • Remibrutinib
  • Study Batoclimab in participants with Thyroid Eye Disease

    The objective of this clinical trial is to investigate the efficacy of batoclimab, a medication delivered subcutaneously, in managing active thyroid eye disease. Participants will be administered batoclimab at a dose of 680 mg once a week for the initial 12 weeks, followed by a reduced dose of 340 mg once a week for an additional 12 weeks. This treatment approach will be compared to a placebo (substance no therapeutic effect). The primary focus of the study is to assess responder rate at Week 24, indicating the proportion of participants experiencing a positive response to treatment. Throughout the 24-week duration of the study, participants will undergo regular monitoring, and assessments to gather comprehensive data on the efficacy, safety, and tolerability of batoclimab.

    • Batoclimab
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    • Ozanimod
  • Study on a new combination therapy for active ulcerative colitis

    This study aims to assess the effectiveness and safety of new combination therapy with JNJ-78934804 (Guselkumab/Golimumab) in comparison to guselkumab and golimumab administred alone for individuals with moderately to severely active ulcerative colitis. Participants who have shown inadequate response, loss of response, or intolerance to approved advanced therapies will be included. The trial includes various treatment groups: placebo, Guselkumab, Golimumab, and different doses of JNJ-78934804. All participants meeting inadequate response criteria will be escalated to an active treatment. The study will last for 48 weeks and the progress will be tracked over this period. The primary focus is to evaluate the efficacy and safety of the different doses of new therapy in managing ulcerative colitis over the course of the study.

    • JNJ-78934804/guselkumab + golimumab
    • Golimumab
    • Guselkumab
  • Long-term study on the effectiveness of mirikizumab for Crohn’s Disease

    This research study is about a long-term test of a medicine called Mirikizumab for people who have Crohn’s disease. The main aim of this study is to know if the medicine is effective and safe for those people eventually. The effect of the medicine will be checked using different tests and scores like the Simple Endoscopic Score for Crohn’s Disease, the Crohn’s Disease Activity Index, and patient-reported outcomes. Researchers will also be checking changes in certain markers in the blood and stool that can show inflammation.

    • Mirikizumab
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    • Ozanimod
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    • Milvexian
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    • Milvexian
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab

See more clinical trials in other cities in Slovakia:

.